Keith Stanley Usiskin

US Patent:

20190112608, Apr 18, 2019

Filed:

Dec 23, 2015

Appl. No.:

15/539497

Inventors:

- Summit NJ, US
Xiaobin LI - Belle Mead NJ, US
Guillermo ROSSITER - Ramsey NJ, US
Philippe L. MARTIN - Hoboken NJ, US
Seth R. DEWACKER - Bridgewater NJ, US
Keith USISKIN - Mendham NJ, US
Gary Allan CLINE - Basking Ridge NJ, US

International Classification:

C12N 15/113
A61P 1/00

Abstract:

Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.

US Patent:

20180344756, Dec 6, 2018

Filed:

Jul 20, 2018

Appl. No.:

16/040580

Inventors:

- Beerse, BE
Keith S. Usiskin - Mendham NJ, US

International Classification:

A61K 31/7042
A61K 38/05
A61K 45/06
A61K 31/4184
A61K 31/4178
A61K 31/41
A61K 31/55
A61K 31/401
A61K 31/4164
A61K 31/4439

Abstract:

The present invention is directed to methods for treating, delaying, slowing the progression of and/or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) canagliflozin and (b) one or more ACE inhibitors or one or more ARBs or one or more PPAR-gamma agonists; and to methods for treating, delaying, slowing the progression of and/or preventing fatty liver disorders (for example, NASH or NAFLD), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin.

US Patent:

20160339047, Nov 24, 2016

Filed:

Jan 30, 2015

Appl. No.:

15/112786

Inventors:

- Beerse, BE
Keith S. Usiskin - Mendham NJ, US

International Classification:

A61K 31/7042
A61K 31/401
A61K 31/41
A61K 31/4184
A61K 31/4178
A61K 31/55
A61K 38/05

Abstract:

The present invention is directed to methods for treating, delaying, slowing the progression of and/or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) canagliflozin and (b) one or more ACE inhibitors or one or more ARBs or one or more PPAR-gamma agonists; and to methods for treating, delaying, slowing the progression of and/or preventing fatty liver disorders (for example, NASH or NAFLD), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin.